A clinical validation study of PatchPump used by Trevyent in healthy adult volunteers.

Trial Profile

A clinical validation study of PatchPump used by Trevyent in healthy adult volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Apr 2018 According to a Cardiome Pharma media release, the company's partner SteadyMed Therapeutics, will resubmite a NDA for Trevyent to FDA. This resubmission is based on the FDA's feedback after an in-person Type A meeting and the certain in vitro pre-design verification (pre-DV) tests. SteadyMed expectes for filing by the end of 2018. Cardiome Pharma plans to submit a regulatory filing for Trevyent in Europe shortly following SteadyMed's NDA resubmission to the FDA.
    • 13 Nov 2017 According to a SteadyMed Therapeutics media release, company held an in-person Type A meeting with FDA and has agreed to a path forward with FDA that it expects will allow for the resubmission and acceptance of Trevyent NDA.
    • 28 Sep 2017 According to a SteadyMed Therapeutics media release, the company has submitted a Type A Meeting Request and Briefing Document to the U.S. Food and Drug Administration (FDA) in response to a Refusal to File letter relating to its New Drug Application (NDA) for Trevyent.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top